OBJECTIVES: Non-cystic fibrosis bronchiectasis (NCFB) may lead to an increased risk of lung infection and cause permanent lung damage. Its exact pathogenesis and epidemiology is not well understood. This study evaluated current treatment patterns and healthcare resource utilization (HRU) associated with NCFB patients in the United States who have experienced ≥1 exacerbation. METHODS: A descriptive retrospective database analysis was conducted using Truven Health’s MarketScan Commercial Claims and Encounters and Medicare Supplemental Databases (containing more than 100 million unique patients) to identify patients with an NCFB exacerbation from 7/1/2008-8/31/2012. Adults ≥18 years had an outpatient claim or inpatient admission for bronchiectasis with or without acute exacerbation as the primary diagnosis (ICD-9-CM codes 494.1 or 494.0; first event defined as index date) and a prescription filled within 7 days for an antibiotic indicative of an exacerbation. Patients had 6 months of pre-index data (baseline period) and 2 years of post-index data (follow-up period) and were stratified according to the number of exacerbations they experienced. All-cause inpatient, outpatient, emergency room, and office visits were recorded for each group. This analysis focused on the first year of follow-up. RESULTS: A total of 5,847 patients met inclusion criteria (mean age±SD 64.05±15.18, 70.0% female). During the first year of follow-up, the proportion of patients experiencing 1, 2, and 3+ exacerbations was 75.9%, 16.0%, and 7.9%, respectively (overall mean exacerbations were 1.36±0.78). A total of 22.2%, 24.0%, and 34.4% of patients with 1, 2, and 3+ exacerbations had an inpatient visit with a mean hospital length of stay of 6.91±9.83, 7.25±6.89, and 9.31±8.64, respectively. Mean annual outpatient visits were 10.83±15.13, 13.19±16.32, and 21.00±22.28, respectively.  CONCLUSIONS: Patients with NCFB utilize substantial healthcare resources in the year following an exacerbation. Therapeutic interventions aimed at reducing frequency of exacerbations may decrease HRU and associated costs.